Showing recent highlights
What's New
PubMed · September 1, 2026
A study found that for people hospitalized with a serious condition called acute-on-chronic liver failure — where the liver suddenly gets much worse on top of long-term liver disease — starting antifungal treatment right away based on suspicion of a fungal infection led to significantly better survival than waiting for lab tests to confirm the infection first. Specifically, researchers found that 35% of patients who received early antifungal treatment survived to 28 days, compared to only 13% of those who waited for test results before starting treatment. This is early research and hasn't yet changed treatment guidelines.
What's New
JAMA · August 4, 2026
Researchers reviewed what is currently known about liver disease caused by long-term heavy alcohol use, looking at how common it is, how doctors identify it, and what treatments exist. This kind of liver disease can range from mild liver inflammation all the way to serious scarring (called cirrhosis), where the liver loses its ability to work properly, and understanding it better could help doctors catch it earlier and manage it more effectively in people who have it. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people with chronic liver disease — a long-term condition where the liver is damaged over time — who took statins (cholesterol-lowering medications) were significantly less likely to develop liver cancer or experience serious liver complications, like the liver suddenly failing to do its job. The association was strong across millions of patients in dozens of countries, though the benefit appeared even greater in Asian populations than in Western ones. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
ScienceDaily · July 25, 2026
A major long-term study found that drinking coffee — even just one or two cups a day, with the strongest benefits seen at three to four cups daily — was linked to lower chances of serious liver problems, including liver scarring (where healthy tissue is replaced by tough, fibrous tissue), liver cancer, and death from liver disease. People who drank coffee also showed less fat and inflammation in their livers on scans and in blood tests. These findings applied to people with fatty liver disease, suggesting regular coffee drinking may play a role in protecting the liver over time.
What's New
PubMed · July 1, 2026
Researchers found that a natural plant compound called oxymatrine — extracted from an herb — may help protect the liver in several ways, including reducing inflammation, fighting harmful cell damage, and slowing the buildup of scar tissue in the liver. For people with fatty liver disease (a condition where too much fat builds up in liver cells, which can lead to serious damage over time), this is interesting because the compound seemed to help the body process fats more effectively and reduce the kind of inflammation that makes fatty liver worse. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that tracking changes in liver stiffness over time — measured with a painless ultrasound-based scan — can help predict serious liver complications in people with chronic liver disease. People whose liver stiffness improved significantly were much less likely to develop serious liver problems, while those whose stiffness worsened (especially people who started with a healthier liver and then showed signs of scarring) faced a notably higher risk. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that certain non-invasive scoring tools — meaning tests that don't require surgery or a biopsy — can do a good job of predicting which people with advanced chronic liver disease might experience a serious complication called 'decompensation,' where the liver begins to fail at key functions like filtering toxins. Two tools in particular, called the SAVE score and ABC score, showed strong accuracy in identifying higher-risk patients across a large review of nearly 48,000 people. This could matter because catching that risk early might open the door to closer monitoring or earlier care conversations — though this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that liver specialists (hepatologists) who received special training in palliative care — a type of support focused on comfort and quality of life for people with serious illness — were just as effective at improving patients' well-being as dedicated palliative care specialists. This was tested in people with advanced liver disease across 19 U.S. medical centers, and it matters because many patients with serious liver disease don't have easy access to palliative care specialists, so having their liver doctor provide that same support could help close that gap. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 18, 2026
A study found that people with chronic liver disease who took a medication called ursodeoxycholic acid (UDCA) — a bile acid pill that helps protect liver cells — saw greater improvements in liver enzyme levels and liver scarring (called fibrosis, where healthy liver tissue gets replaced by scar tissue) compared to those who took a placebo, or dummy pill, over 8 weeks. Researchers also found the medication appeared safe, with no serious side effects reported in the treatment group. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · April 1, 2026
According to the European Association for the Study of the Liver (EASL), people with advanced chronic liver disease — a condition where the liver is severely damaged and struggling to work — often don't receive proper comfort-focused care until the very end of their life, and may go through unnecessary invasive procedures in the meantime. EASL now recommends that clinicians bring in palliative care — support focused on easing symptoms, pain, and emotional distress — much earlier in the process, not just in a patient's final days. This matters because getting that support sooner can meaningfully improve quality of life for people living with this serious condition.
What's New
PubMed · February 27, 2026
A study found that people with advanced liver disease who received a structured supportive care program — where a team of health professionals met regularly with patients and their caregivers to address their specific needs — had 66% fewer emergency department visits and 64% fewer hospital stays over 90 days compared to those receiving standard care alone. They were also five times more likely to spend more days alive and at home rather than in a hospital, and the overall cost of their care was cut by more than half. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.